Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications

Stefaniak, J., Lewis, A. M., Conole, D., Galan, S., Bataille, C., Wynne, G. M., … Huber, K. (2018). Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors. ACS Chemical Biology, 13(10), 2849–2854.

Date
Wed, 19/09/2018 - 12:00
PubMed ID
30216042
Author(s)
Stefaniak J, Lewis AM, Conole D, Galan SRG, Bataille CJR, Wynne GM, Castaldi MP, Lundbäck T, Russell AJ, Huber KVM
Year
2018
EFPIA partners
AstraZeneca
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility